Product Overview
Retatrutide 30mg Canada - LY3437943 Research Peptide
Retatrutide 30mg from Precision Synthetics Canada is a lyophilized research peptide supplied in a sealed 3 mL glass vial for laboratory research and analytical use.
Retatrutide, also known as LY3437943 or LY-3437943, is studied as a triple receptor agonist across the glucagon, GIP, and GLP-1 receptor pathways. Its multi-incretin profile has made it a high-interest compound in research involving body-weight models, metabolic signaling, receptor activity, glycemic endpoints, energy expenditure, and body-composition research.
Precision Synthetics Canada takes a safety-first approach to research peptide supply. Each released batch is supported by Janoshik source-lab documentation, independent Testide Canada Laboratory verification, and LAL endotoxin screening through Testide for supported batches. This gives Canadian research buyers more than a purity percentage by adding visibility into identity, purity, batch traceability, and endotoxin screening.
Key Highlights
- 30 mg lyophilized Retatrutide per vial
- Also known as Retatrutide, LY3437943, and LY-3437943
- Triple GCGR / GIPR / GLP-1R receptor agonist research compound
- Sealed 3 mL glass vial with batch-labeled traceability
- Janoshik Laboratory source-lab documentation
- Independent Testide Canada Laboratory verification arranged by Precision Synthetics Canada
- LAL endotoxin screening through Testide for added batch-quality review
- COA access for supported batches
- Ships from Vancouver, Canada
Beyond Purity: LAL Endotoxin Screening
Many research peptide listings stop at HPLC purity. Precision Synthetics Canada uses a safety-first batch review model that pairs Janoshik source-lab documentation with Testide Canada Laboratory verification and LAL endotoxin screening on supported batches.
LAL endotoxin screening helps assess bacterial endotoxin presence in the submitted sample. For research buyers comparing suppliers, this adds a meaningful quality-control datapoint beyond purity percentage alone before selecting Retatrutide research material.
Dual Third-Party Testing + LAL Endotoxin Screening
Each released batch is supported by two layers of third-party documentation.
- Janoshik Laboratory: source-lab testing documentation connected to the originating production batch.
- Testide Canada Laboratory: independent verification arranged by Precision Synthetics Canada before the batch is made available, including LAL endotoxin screening for supported batches.
This model gives research buyers more transparency than relying on a single supplier document. for supported batches, batch documentation may include identity confirmation, purity analysis, chromatogram data, report date, sample reference, batch linkage, LAL endotoxin screening, and verifiable report information.
COA Transparency
COA access is provided for supported batches through batch-linked documentation, QR code access, or a product documentation page. For more information, visit COA Transparency.
Some Janoshik source-lab COAs may include limited redactions to protect upstream laboratory confidentiality and prevent unauthorized or unsolicited contact with source-lab partners. These redactions may apply to identifying or commercially sensitive details and are not intended to obscure analytical results.
Research Profile
Retatrutide is studied as a multi-incretin research peptide because of its activity across three receptor pathways:
| Pathway | Research Relevance |
|---|---|
| GCGR | Glucagon receptor pathway research |
| GIPR | Glucose-dependent insulinotropic polypeptide receptor research |
| GLP-1R | Glucagon-like peptide-1 receptor research |
Common research areas include:
- Body-weight and obesity research models
- Triple glucagon/GIP/GLP-1 receptor agonism
- Multi-incretin pathway signaling
- cAMP signaling and receptor potency studies
- Receptor selectivity and comparative activity
- Glycemic endpoint research
- Insulin-response and metabolic biomarker models
- Energy expenditure and food-intake research models
- Body weight, fat mass, and lean mass partitioning models
- Comparative pharmacology involving semaglutide, tirzepatide, and other incretin analogs
- Analytical identity, purity, endotoxin screening, and batch-to-batch review
Retatrutide is sometimes searched informally as "triple GLP" or "GLP-3", but the accurate research description is triple glucagon/GIP/GLP-1 receptor agonist.
Product Details
| Specification | Details |
|---|---|
| Product name | Retatrutide 30mg |
| Brand | Precision Synthetics Canada |
| Synonyms | LY3437943, LY-3437943 |
| Product type | Research peptide |
| Research class | Triple glucagon/GIP/GLP-1 receptor agonist |
| Net content | 30 mg per vial |
| Format | Lyophilized material |
| Appearance | White to off-white lyophilized material |
| Container | Sealed 3 mL glass vial |
| Approximate vial weight | 0.005 kg, about 5 g |
| Lot/batch ID | Recorded on vial label |
| Testing model | Janoshik source-lab documentation + Testide Canada Laboratory verification |
| Endotoxin screening | LAL endotoxin screening through Testide Canada Laboratory for supported batches |
| COA access | Batch-linked documentation for supported batches |
| Shipping origin | Vancouver, Canada |
| Shipping availability | Canada only |
| Intended use | Research use only |
Compound Identity
| Field | Information |
|---|---|
| Compound | Retatrutide |
| Synonyms | LY3437943, LY-3437943 |
| CAS | 2381089-83-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | Approximately 4731.35 g/mol |
| Research category | Long-acting multi-incretin analog |
| Receptor pathways | GCGR, GIPR, GLP-1R |
Canadian Shipping
Orders ship from Vancouver, Canada. Shipping is currently available within Canada only.
Intended Use
Retatrutide 30mg is supplied for laboratory research, analytical reference work, assay development, and non-clinical research applications.
FAQ
What is Retatrutide?
Retatrutide, also known as LY3437943 or LY-3437943, is a synthetic research peptide studied for activity across the glucagon, GIP, and GLP-1 receptor pathways.
Is this Retatrutide third-party tested?
Yes. Each released batch is supported by Janoshik source-lab documentation and independent Testide Canada Laboratory verification arranged by Precision Synthetics Canada.
Does this product include LAL endotoxin screening?
Released batches include LAL endotoxin screening through Testide Canada Laboratory for supported batches. This adds another quality-control datapoint for research buyers.
Does this product include a COA?
Applicable released batches are supported by batch-linked COA documentation. COA access may be provided through a QR code, report link, or batch documentation page.
Where does this product ship from?
Retatrutide 30mg ships from Vancouver, Canada, with shipping currently available within Canada only.
Is Retatrutide the same as GLP-3?
No. "GLP-3" is an informal search term sometimes used online. The accurate research description is triple glucagon/GIP/GLP-1 receptor agonist.
